Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

	APEUTICS, INC	C.									
Form 4 March 25, 20)14										
FORM	1 /								OMB AF	PROVAL	
Washington, D.C. 20549									OMB Number:	3235-0287	
Check this box if no longer subject to STATEMENT OF CHAN						CIA	L OWN	ERSHIP OF	Expires: Janual Estimated average		
Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	r Filed pu ns Section 17	7(a) of the 1	Public U		e Securiti ling Com	ipany	Act of	Act of 1934, 1935 or Sectior)	burden hour response	rs per 0.5	
(Print or Type I	Responses)										
Peltz Stuart Walter Symbol				r Name and Ticker or Trading HERAPEUTICS, INC.				5. Relationship of Reporting Person(s) to Issuer			
[PT					,			(Check all applicable)			
(Last) (First) (Middle) 3. Date of (Month/E C/O PTC THERAPEUTICS, 03/24/2				-				_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer			
INC., 100 C	ORPORATE C	COURT									
SOUTH PL	(Street) AINFIELD, NJ	07080		endment, Da hth/Day/Year	-			6. Individual or Joi Applicable Line) _X_ Form filed by O Form filed by M	ne Reporting Per	rson	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	Securi		Person uired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		Fransaction Date 2A. Deemed onth/Day/Year) Execution Date, if any (Month/Day/Year)			4. Securiti n(A) or Dis (Instr. 3, 4	(A) or	quired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. 7. Nature of Ownership Indirect Form: Direct Beneficial (D) or Ownership Indirect (I) (Instr. 4) (Instr. 4)		
Common Stock	03/24/2014			Code V $S(\underline{1})$	Amount 151	(D) D	Price \$ 27.39	161,238	D		
Common Stock	03/24/2014			S <u>(1)</u>	9,022	D	\$ 29.08 (2)	152,216	D		
Common Stock	03/24/2014			S <u>(1)</u>	10,600	D	\$ 30.1 (3)	141,616	D		
Common Stock	03/24/2014			S <u>(1)</u>	5,714	D	\$ 30.73 (4)	135,902	D		

Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title	of 2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Title and	8. Price of	9. Nu
Derivati	ve Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration D	ate	Amount of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underlying	Security	Secu
(Instr. 3) Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e		Securities	(Instr. 5)	Bene
	Derivative				Securities	5		(Instr. 3 and	4)	Owne
	Security				Acquired					Follo
					(A) or					Repo
					Disposed					Trans
					of (D)					(Instr
					(Instr. 3,					
					4, and 5)					
								Amo	unt	
									unt	
						Date	···· r ··· ·	or Title Num	ber	
						Exercisable		Title Numbe of	UCI	
				Code V	(A) (D)			Share	26	

Reporting Owners

Reporting Owner Name / Address	Relationships						
reporting o when runno, maaroos	Director	10% Owner	Officer	Other			
Peltz Stuart Walter C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD, NJ 07080	Х		Chief Executive Officer				
Signatures							
/s/ Colleen Diver Johnson, attorney-in-fact		03/25/2014					
**Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on August 16, 2013 for the primary purpose of covering tax obligations associated with a restricted stock vesting event.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$28.48
 (2) to \$29.48 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$29.49(3) to \$30.49 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$30.50

(4) to \$31.00 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.